The aging patient with hemophilia

American Journal of Hematology

Volumn 87, Issue SUPPL. 1, 2012, Pages

  Konkle, Barbara A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGING; ANKYLOSIS; ANTICOAGULANT THERAPY; ARTHRODESIS; ARTHROPATHY; ATHEROGENESIS; ATHEROSCLEROSIS; BLEEDING; BONE CYST; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTRACTURE; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; END STAGE LIVER DISEASE; HEART CATHETERIZATION; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEMARTHROSIS; HEMATURIA; HEMODIALYSIS; HEMOPHILIA; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY HEMORRHAGE; LIVER FAILURE; LIVER TRANSPLANTATION; MUSCLE ATROPHY; NONHUMAN; OSTEOPOROSIS; PERITONEAL DIALYSIS; PHYSIOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYNOVECTOMY; THROMBOSIS;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; CARDIOVASCULAR DISEASES; FEMALE; HEMOPHILIA A; HUMANS; KIDNEY DISEASES; LIVER DISEASES; MALE; MUSCULOSKELETAL DISEASES; PREVALENCE;

EID: 84859998478     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23161     Document Type: Review

References (93)

1. Plug I, van der Born JG, Peters M, et al. Mortality and causes of death in patients with hemophilia 1992-2001: A prospective cohort study. J Thromb Hemost 2006; 4: 510-516.
2. Chorba TL, Holman RC, Clarke MJ, Evatt BL. Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States. Am J Hematol 2001; 66: 229-240.
3. Ragni MV, Sherman KE, Jordan JA. Viral pathogens. Hemophilia 2010: 16(Suppl 5): 40-46.
4. Darby SC, Kan SW, Spooner RJ, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007; 110: 815-825.
5. Arnold DM, Julian JA, Walker IR. Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21 years of years of follow up. Blood 2006; 108: 460-464.
6. Ljung R. Prophylactic therapy in hemophilia. Blood Rev 2009; 23: 267-274.
7. Tagliaferri A, Franchini M, Coppola A, et al. Effects of secondary prophylaxis started in adolescent and adult hemophiliacs. Hemophilia 2008; 14: 945-951.
8. Collins P, Faradji A, Morfini M, et al. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Hemost 2010; 8: 83-89.
9. Siboni SM, Mannucci PM, Gringeri A, et al. Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy. J Thromb Hemost 2009; 7: 780-786.
10. Leissinger C, Cooper DL, Solem CT, on behalf of the HTRS Investigators. Assessing the impact of age, race, ethnicity and inhibitor status on functional limitations of patients with severe and moderately severe hemophilia A. Hemophilia 2011; 17: 884-889.
11. Kempton CL, Soucie JM, Miller CH, et al. In nonsevere hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: A case-control study. J Thromb Hemost 2010; 8: 2224-2231.
12. Hay CRM, Palmer B, Chalmers E, et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011; 117: 6367-6370.
13. Kastl SP, Speidl WS, Katsaros KM, et al. Thrombin induces the expression of oncostatin M via AP-1 activation in human macrophages: A link between coagulation and inflammation. Blood 2009; 114: 2812-2818.
14. Fabri DR, DePaula EV, Costa DSP, et al. Novel insights into the development of atherosclerosis in hemophilia A mouse models. J Thromb Hemost 2011; 9: 1556-1561.
15. Tuinenburg A, Mauser-Bunschoten EP, Verhaar MC, et al. Cardiovascular disease in patients with hemophilia. J Thromb Hemost 2009; 7: 247-254.
16. Biere-Rafi S, Zwiers M, Peters M, et al. The effect of haemophilia and von Willebrand disease on arterial thrombosis: A systematic review. Neth J Med 2010; 68: 207-214.
17. Foley CJ, Nichols L, Jeong K, et al. Coronary atherosclerosis and cardiovascular mortality in hemophilia. J Thromb Haemost 2010; 8: 208-211.
18. Zwiers M, Lefrandt JD, Mulder DJ, et al. Coronary artery calcification score and carotid intima-media thickness in patients with hemophilia. J Thromb Haemost 2012; 10: 23-29.
19. Siere-Rafi S, Tuinenburg A, Haak BW, et al. Factor VIII deficiency does not protect against atherosclerosis. J Thromb Haemost 2012; 10: 30-37.
20. Kulkarni R, Soucie JM, Evatt BL. Prevalence and risk factors for heart disease among males with hemophilia. Am J Hematol 2005; 79: 36-42.
21. Soucie JM, Nuss R, Evatt B, et al. Mortality among males with hemophilia: Relations with source of medical care. Blood 2000; 96: 437-442.
22. Sharathkumar AA, Soucie JM, Trawinski B, et al. Prevalence and risk factors of cardiovascular disease events among patients with haemophilia: Experience of a single haemophilia treatment centre in the United States. Haemophilia 2011; 17: 597-604.
23. Biere-Rafi S, Baarslag MA, Peters M, et al. Cardiovascular risk assessment in haemophilia patients. Thromb Haemost 2011; 105: 274-278.
24. Sramek A, Kriek M, Rosendaal FR. Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet 2003; 362: 351-354.
25. Konkle BA, Kessler C, Aledort L, et al. Emerging clinical concerns in the ageing haemophilia patient. Haemophilia 2009; 15: 1197-1209.
26. Rosendaal FR, Briet E, Stibbe J, et al. Haemophilia protects against ischaemic heart disease: A study of risk factors. Br J Haematol 1990; 75: 525-530.
27. Ragni MV, Moore CG. Athersclerotic heart disease: Prevalence and risk factors in hospitalized men with haemophilia A. Haemophilia 2011; 17: 867-871.
28. Kulkarni R, Soucie JM, Evatt B. Renal disease among males with haemophilia. Haemophilia 2003; 9: 703-710.
29. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet 2010; 375: 2073-2081.
30. Wong TE, Majumdar S, Adams E, et al. Overweight and obesity in hemophilia: A systematic review of the literature. Am J Prev Med 2011; 41(Suppl 4): S369-S375.
31. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506-2512.
32. Guiltinan AM, Kaidzrova Z, Custer B, et al. Increased all-cause, liver, and cardiac mortality among hepatitis C virus seropositive blood donors. Am J Epidemiol 2008; 167: 743-750.
33. Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: State of the art and future perspectives. Ann Rheumat Dis 2011; 70: 8-14.
34. Huang C-F, Hsieh M-Y, Yang J-F, et al. Serum hs-CRP was correlated with treatment response to pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients. Hepatol Int 2010; 4: 621-627.
35. Mannucci PM, Schutgens REG, Santagostino E, Mauser-Bunschoten EP. How I treat age-related morbidities in elderly persons with hemophilia. Blood 2009; 114: 5256-5263.
36. Copploa A, Tagliaferri A, Franchini M. The management of cardiovascular diseases in patients with hemophilia. Semin Thromb Hemost 2010; 36: 91-102.
37. Inwood MJ, Killackey B, Startup SJ. The use and safety of ibuprofen in the hemophiliac. Blood 1983; 61: 709-711.
38. Eyster ME, Asaad SM, Gold BD, et al. Upper gastrointestinal bleeding in haemophiliacs: Incidence and relation to use of nonsteroidal antiinflammatory drugs. Haemophilia 2007; 13: 279-286.
39. Girolami A, Scandellari R, Zanon E, et al. Noncatheter associated venous thrombosis in hemophilia A and B. A critical review of all reported cases. J Thromb Thrombol 2006; 21: 279-284.
40. Girolami A, Randi ML, Ruzzon E, et al. Myocardial infarction, other arterial thrombosis and invasive coronary procedures, in hemophilia B: A critical evaluation of reported cases. J Thromb Thrombol 2005; 20: 43-46.
41. Cid A, Zorio E, Haya S, et al. Treatment in a haemophiliac A patient with paroxysmal atrial fibrillation and ischemic heart disease. Haemophilia 2007; 13: 760-762.
42. Giersdorf G, Huth-Kuhne A, Zimmermann R. Anticoagulation in a patient with hemophilia B and mechanic heart valve replacement. Haemophilia 2010; 16; 23 (abstract).
43. Street A, Hill K, Sussex B, et al. Haemophilia and ageing. Haemophilia 2006; 12: 8-12.
44. Dauerman HL, Rao SV, Resnic FS, Applegate RJ. Bleeding avoidance strategies: Consensus and controversy. J Am Coll Cardiol 2011; 58: 1-10.
45. Werner GS, Schwarz G, Prochnau D, et al. Paclitaxel-eluting stents for the treatment of chronic total coronary occlusions: A strategy of extensive lesion coverage with drug-eluting stents. Catheter Cardiovasc Interv 2006; 67: 1-9.
46. Helft G, Gilard M, Le Feuvre C, Zaman AG. Drug insight: Antithrombotic therapy after percutaneous coronary intervention in patients with an indication for anticoagulation. Nat Clin Pract Cardiovasc Med 2006; 3: 673-680.
47. Seung KB, Park DW, Kim YH, et al. Stents versus coronary-artery bypass grafting for left main coronary artery disease. N Engl J Med 2008; 358: 1781-1792.
48. American Heart Association. Recommended schedule for screening tests. Available at:.
49. Pergantou H, Matsinos G, Papadopoulos A, et al. Comparative study of validity of clinical, X-ray and magnetic resonance imaging scores in evaluation and management of haemophilic arthropathy in children. Haemophilia 2006; 12: 241-247.
50. Arnold WD, Hilgartner MW. Hemophilic arthropathy. Current concepts of pathogenesis and management. J Bone Joint Surg Am 1977; 59: 287-305.
51. Hoots WK. Pathogenesis of hemophilic arthropathy. Semin Hematol 2006; 43: S18-S22.
52. Roosendaal G, Lafeber FP. Blood-induced joint damage in hemophilia. Semin Thromb Hemost 2003; 29: 37-42.
53. Gianotten WL, Heijnen L. Haemophilia, aging and sexuality. Haemophilia 2009; 15: 55-62.
54. Bar-Chama N, Snyder S, Aledort L. Sexual evaluation and treatment of ageing males with haemophilia. Haemophilia 2011; 17: 875-883.
55. Manco-Johnson MJ, Nuss R, Gerahty S, et al. Results of secondary prophylaxis in children with severe hemophilia. Am J Hematol 1994; 47: 113-117.
56. Tagliaferri A, Rivolta GF, Rossetti G, et al. Experience of secondary prophylaxis in 20 adolescent and adult Italian hemophiliacs. Thromb Haemost 2006; 96: 542-543.
57. Siegel HJ, Luck JV, Siegel ME, Quinones C. Phosphate-32 colloid radiosynovectomy in hemophilia: Outcome of 125 procedures. Clin Orthop Relat Res 2001;392: 409-417.
58. Dunn AL, Busch MT, Wyly JB, et al. Arthroscopic synovectomy for hemophilic joint disease in a pediatric population. J Pediatr Orthop 2004; 24: 414-426.
59. Journeycake JM, Miller KL, Anderson AM, et al. Arthroscopic synovectomy in children and adolescents with hemophilia. J Pediatr Hematol Oncol 2003; 25: 726-731.
60. Luck JV, Silva M, Rodriguez-Merchan EC, et al. Hemophilic arthropathy. J Am Acad Orthop Surg 2004; 12: 234-245.
61. Rivard GE, Girard M, Belanger R, et al. Synoviorthesis with colloidal 32P chromic phosphate for the treatment of hemophilic arthropathy. J Bone Joint Surg Am 1994; 76: 482-488.
62. Goddard NJ. Joint replacement. In: Lee CA, Berntorp EE, Hoots WK, editors. Textbook of Hemophilia. Malden, Mass: Blackwell Publishing; 2005. pp 164-168.
63. Goddard NJ, Rodriguez-Merchan EC, Wiedel JD. Total knee replacement in haemophilia. Haemophilia 2002; 8: 382-386.
64. Forsyth AL, Quon DV, Konkle BA. Role of exercise and physical activity on hemophilic arthropathy, fall prevention and osteoporosis. Haemophilia 2011; 17: e870-e876.
65. Wallny TA, Scholz DT, Oldenburg J, et al. Osteoporosis in haemophilia-An underestimated comorbidity? Haemophilia 2007; 13: 79-84.
66. Khawaji M, Astermark J, von Mackensen S, et al. Bone density and health-related quality of life in adult patients with severe haemophilia. Haemophilia 2011; 17: 304-311.
67. Mansouritorghabeh HR. Bleeding disorders and reduced bone density. Rheumatol Int 2011; 31: 283-287.
68. Glimet T, Masse JP, Kuntz D. Obesity and degenerative knee arthritis. Revue Du Rhumatisme 1990; 57: 207-209.
69. Darby SC, Ewart DW, Giangrande PL, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997; 350: 1425-1431.
70. Makris M, Preston FE, Rosendaal FR, et al. The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol 1996; 94: 746-752.
71. Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 2001; 183: 1112-1115.
72. Yee TT, Griffioen A, Sabin CA, et al. The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Gut 2000; 47: 845-851.
73. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
74. Telfer P, Sabin C, Devereux H, et al. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol 1994; 87: 555-561.
75. Ragni MV, Nalesnik MA, Schillo R, Dang Q. Highly active antiretroviral therapy improves ESLD-free survival in HIV-HCV coinfection. Haemophilia 2009; 15: 552-558.
76. Goedert JJ, Eyster ME, Lederman MM, et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 2002; 100: 1584-1589.
77. Daar ES, Lynn H, Donfield S, et al. Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J Acquir Immune Defic Syndr 2001; 26: 466-472.
78. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362: 1708-1713.
79. Ragni MV, Moore CG, Soadwa K, et al. Impact of HIV on liver fibrosis in men with hepatitis C infection and haemophilia. Haemophilia 2011; 17: 103-111.
80. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500.
81. DiMichele DM, Mirani G, Canchis PW, et al. Transjugular liver biopsy is safe and diagnostic for patients with congenital bleeding disorders and hepatitis C infection. Haemophilia 2003; 9: 613-618.
82. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet 2001; 357: 1069-1075.
83. Sebastiani G, Castera L, Halfon P, et al. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of noninvasive fibrosis biomarkers: An international study of 2411 cases. Aliment Pharmacol Ther 2011; 34: 1202-1216.
84. Asselah T. A sprint to increase response to HCV treatment: Expectancies but caution. Int J Hepatol 2011; 55: 1154-1158.
85. Ragni MV, Eghtesad B, Schlesinger KW, et al. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl 2005; 11: 1425-1430.
86. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-1491.
87. Tradati F, Colombo M, Mannucci PM, et al. A prospective multicenter study of hepatocellular carcinoma in Italian hemophiliacs with chronic hepatitis C. Blood 1998; 91: 1173-1177.
88. Froom P, Ribak J, Benbassat J. Significance of microhaematuria in young adults. Br Med J 1984; 288: 20-22.
89. Szczech LA. Renal diseases associated with human immunodeficiency virus infection: epidemiology, clinical course, and management. Clin Infect Dis 2001; 33: 115-119.
90. Rao TK. Human immunodeficiency virus infection and renal failure. Infect Dis Clin North Am 2001; 15: 833-850.
91. Roy-Chaudhury P, Propper DJ, Catto GRD. Renal replacement therapy for hemophiliacs. J Nephrol 1993; 6: 93-94.
92. Fujii T, Takata N, Saito S, et al. Management of haemostasis during haemodialysis in a patient with haemophilia B. Haemophilia 2008; 14: 1135-1137.
93. Bajo MA, del Peso G, Jimenez V, et al. Peritoneal dialysis is the therapy of choice for end-stage renal disease patients with hereditary clotting disorders. Adv Perit Dial 2000; 16: 170-173.